The Covid war has been immensely profitable for Moderna and Pfizer. For example, Pfizer’s revenue in 2021 was more than $80 billion, doubling its 2020 revenue. Its mRNA vaccine formulations have majority market share in the United States and Europe, and Paxlovid is the best early stage Covid drug. In 2022 the Covid vaccines and drugs alone are expected to bring in more than $50 billion in revenue, worldwide. Pfizer has gained growing influence over the nature and timing of future Covid vaccines.15
